Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
Ruth Scheicher, Andrea Hoelbl‐Kovacic, Florian Bellutti, et al.
Blood (2014) Vol. 125, Iss. 1, pp. 90-101
Open Access | Times Cited: 215

Showing 1-25 of 215 citing articles:

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng, Eric S. Wang, Russell W. Jenkins, et al.
Cancer Discovery (2017) Vol. 8, Iss. 2, pp. 216-233
Open Access | Times Cited: 610
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 17, pp. 5218-5224
Open Access | Times Cited: 607
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Per Hydbring, Marcos Malumbres, Piotr Siciński
Nature Reviews Molecular Cell Biology (2016) Vol. 17, Iss. 5, pp. 280-292
Open Access | Times Cited: 458
Targeting CDK4/6 in patients with cancer
Erika Hamilton, Jeffrey R. Infante
Cancer Treatment Reviews (2016) Vol. 45, pp. 129-138
Open Access | Times Cited: 412
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Ping Chen, Nathan V. Lee, Wenyue Hu, et al.
Molecular Cancer Therapeutics (2016) Vol. 15, Iss. 10, pp. 2273-2281
Open Access | Times Cited: 369
CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem Cells
Elisa Laurenti, Catherine Frelin, Stephanie Z. Xie, et al.
Cell stem cell (2015) Vol. 16, Iss. 3, pp. 302-313
Open Access | Times Cited: 301
Cell cycle on the crossroad of tumorigenesis and cancer therapy
Jing Liu, Yunhua Peng, Wenyi Wei
Trends in Cell Biology (2021) Vol. 32, Iss. 1, pp. 30-44
Open Access | Times Cited: 261
Restraining Lysosomal Activity Preserves Hematopoietic Stem Cell Quiescence and Potency
Raymond Liang, Tasleem Arif, Svetlana Kalmykova, et al.
Cell stem cell (2020) Vol. 26, Iss. 3, pp. 359-376.e7
Open Access | Times Cited: 206
Cell-Cycle Proteins Control Production of Neutrophil Extracellular Traps
Borko Amulic, Sebastian Lorenz Knackstedt, Ulrike Abu Abed, et al.
Developmental Cell (2017) Vol. 43, Iss. 4, pp. 449-462.e5
Open Access | Times Cited: 204
Cyclin D-CDK4/6 functions in cancer
Xueliang Gao, Gustavo Leone, Haizhen Wang
Advances in cancer research (2020), pp. 147-169
Closed Access | Times Cited: 156
The role of CDK6 in cancer
Sofie Nebenfuehr, Karoline Kollmann, Veronika Sexl
International Journal of Cancer (2020) Vol. 147, Iss. 11, pp. 2988-2995
Open Access | Times Cited: 139
Targeted therapy for breast cancer: An overview of drug classes and outcomes
Aaron T. Jacobs, Diana Martinez Castaneda-Cruz, Mark M. Rose, et al.
Biochemical Pharmacology (2022) Vol. 204, pp. 115209-115209
Open Access | Times Cited: 87
CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
Erik S. Knudsen, Vishnu Kumarasamy, Ram Nambiar, et al.
Cell Reports (2022) Vol. 38, Iss. 9, pp. 110448-110448
Open Access | Times Cited: 86
Deciphering cell states and genealogies of human haematopoiesis
Chen Weng, Fulong Yu, Dian Yang, et al.
Nature (2024) Vol. 627, Iss. 8003, pp. 389-398
Open Access | Times Cited: 54
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
Cynthia L. Palmer, Britton Boras, Bernadette Pascual, et al.
Cancer Cell (2025) Vol. 43, Iss. 3, pp. 464-481.e14
Open Access | Times Cited: 3
CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation
A-S Tigan, Florian Bellutti, Karoline Kollmann, et al.
Oncogene (2015) Vol. 35, Iss. 24, pp. 3083-3091
Open Access | Times Cited: 161
Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Neil Portman, Sarah Alexandrou, Emma‐Kate Carson, et al.
Endocrine Related Cancer (2018) Vol. 26, Iss. 1, pp. R15-R30
Open Access | Times Cited: 142
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis
Masayuki Yamashita, Paul V. Dellorusso, Oakley C. Olson, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 7, pp. 365-382
Open Access | Times Cited: 127
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
Silvia Paola Corona, Daniele Generali
Drug Design Development and Therapy (2018) Vol. Volume 12, pp. 321-330
Open Access | Times Cited: 118
Targeting cell cycle regulators in hematologic malignancies
Eiman Aleem, R.J. Arceci
Frontiers in Cell and Developmental Biology (2015) Vol. 3
Open Access | Times Cited: 115
Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6
Iris Z. Uras, Gina Walter, Ruth Scheicher, et al.
Blood (2016) Vol. 127, Iss. 23, pp. 2890-2902
Open Access | Times Cited: 111
Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype
Sidinh Luc, Jialiang Huang, Jennifer L. McEldoon, et al.
Cell Reports (2016) Vol. 16, Iss. 12, pp. 3181-3194
Open Access | Times Cited: 101
Regulation of Glycolysis by Non-coding RNAs in Cancer: Switching on the Warburg Effect
Hamed Mirzaei, Michael R. Hamblin
Molecular Therapy — Oncolytics (2020) Vol. 19, pp. 218-239
Open Access | Times Cited: 101
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation
Mara Bonelli, Silvia La Monica, Claudia Fumarola, et al.
Biochemical Pharmacology (2019) Vol. 170, pp. 113676-113676
Closed Access | Times Cited: 85
Niche derived netrin-1 regulates hematopoietic stem cell dormancy via its receptor neogenin-1
Simon Renders, Arthur Flohr Svendsen, Jasper Panten, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 66
Page 1 - Next Page

Scroll to top